Kimberly-Clark agrees to buy Tylenol maker Kenview

On Monday, Kimberly-Clark, the company behind Kleenex, Huggies and Kotex, agreed to acquire Canview, owner of Tylenol, Band-Aid and Neutrogena, in a cash and stock deal worth about $48.7 billion. The move will create one of the world’s largest consumer goods and health goods companies cnbc,

companies said a news release The combined business will generate annual revenues of $32 billion and annual cost savings of approximately $2.1 billion. The acquisition brings together brands including Johnson’s Baby products and Listerine mouthwash for $10 billion and is poised to become one of the biggest deals this year, according to CNBC.

The new company will create products that “will touch nearly half the global population at every stage of life,” the companies said in the release.

Connected: Acquisitions fail when leaders ignore these drivers of business value

The deal will pay Kimberly-Clark $21.01 for each Kenview share, up from its Friday closing price of $14.37. At closing of the transaction, Kimberly-Clark shareholders are expected to own approximately 54% of the combined company, while Kenview shareholders will own approximately 46%. cbs,

The acquisition is subject to shareholder approval and is expected to close in the second half of 2026.

“Over the past several years, Kimberly-Clark has made a significant transformation to pivot our portfolio toward higher-growth, higher-margin businesses, while repositioning our organization to work smarter and faster,” Kimberly-Clark President and CEO Mike Hsu said in the news release.

“We have laid the foundation and this transaction is a powerful next step in our journey,” HSU said in the news release.

Connected: This AI startup received $900 million from Nvidia to hire its CEO and license its technology

Kenview’s shares were more than 16% At the time of writing, shares of Kimberly-Clark were down about 12%,

Canview, a portfolio of consumer health brands, has been subject to public scrutiny following the administration of President Donald Trump Joined together Tylenol pain reliever for autism in September. Kenview has denied the administration’s claims. cnn,

The company informed this third quarter 2025 Results on Monday showed organic sales declined 4.4%, worse than expectedMeanwhile, Kimberly-Clark announced Its third quarter 2025 results last week showed organic sales growth of 2.5% and net sales of $4.2 billion.

Kenview was originally part of Johnson & Johnson, but it was spun off from the company. in may 2023Since that time, Kenview shares have fallen more than 30%. At the time of writing, Kenview traded approx $16 per share For a market capitalization of approximately $32 billion. The market capitalization of Kimberly-Clark was approximately $35 billion,

Connected: Warren Buffett Makes His Biggest Deal in 3 Years, Possibly His Last as CEO

On Monday, Kimberly-Clark, the company behind Kleenex, Huggies and Kotex, agreed to acquire Canview, owner of Tylenol, Band-Aid and Neutrogena, in a cash and stock deal worth about $48.7 billion. The move will create one of the world’s largest consumer goods and health goods companies cnbc,

companies said a news release The combined business will generate annual revenues of $32 billion and annual cost savings of approximately $2.1 billion. The acquisition brings together brands including Johnson’s Baby products and Listerine mouthwash for $10 billion and is poised to become one of the biggest deals this year, according to CNBC.